Physician profile
Katrina Dever
NPI 1073024840
$5,793.36
in general payments reported to CMS, 2019-2025
39 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $823 · 2023: $1,307 · 2024: $1,408 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,362 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,362.19 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $927.84 | 2022-2025 | Apretude |
| Abbvie INC. | $888.41 | 2022-2025 | |
| Lilly USA, LLC | $709.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $528.34 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Gilead Sciences, INC. | $331.92 | 2023-2025 | Yeztugo, Descovy |
| Astellas Pharma US INC | $251.25 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $222.32 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $219.65 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $163.27 | 2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $149.69 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $145.37 | 2022-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Bausch Health US, LLC | $114.40 | 2024-2025 | Aplenzin, Wellbutrin |
| Novartis Pharmaceuticals Corporation | $111.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.49 | 2024-2025 | Trintellix |
| Merz North America, INC. | $106.25 | 2023 | Xeomin |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $82.22 | 2022-2023 | Acthar |
| Amgen INC. | $65.42 | 2025 | Krystexxa |
| Hologic Sales and Service, LLC | $59.32 | 2022-2023 | Aptima |
| Pfizer INC. | $50.97 | 2024-2025 | |
| Kaleo, INC. | $49.82 | 2022 | |
| Dexcom, INC. | $46.84 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $41.73 | 2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $41.71 | 2023-2024 | Gardasil 9, Gardasil, Pneumovax 23 |
| Pharmacyclics LLC, An Abbvie Company | $40.23 | 2022 | |
| Phadia US INC. | $34.82 | 2022-2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $28.58 | 2025 | Zoryve |
| Itamar Medical INC | $26.70 | 2025 | Watchpatone |
| Phathom Pharmaceuticals, INC. | $26.23 | 2025 | Voquezna |
| Shield Therapeutics INC | $24.58 | 2025 | |
| Coherus Oncology, INC. | $22.03 | 2021 | |
| Incyte Corporation | $21.05 | 2021 | |
| Genentech USA, INC. | $20.06 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.76 | 2021 | |
| Dova Pharmaceuticals | $19.56 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.40 | 2023 | Jynarque |
| Janssen Biotech, INC. | $18.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.86 | 2023 | Quviviq |
| Seagen INC. | $18.55 | 2021 | |
| Abbott Laboratories | $17.46 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Dever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.